CAR T-cell therapies have been used to treat cancer patients since 2011, but infection-related adverse events remain a significant hurdle. Often, fever is one of the earliest warning signs of clinical deterioration and a potentially life-threatening condition.
One of the greatest challenges in cancer immunotherapy is finding the rare immune cells, called tumor-reactive T cells, whose job it is to recognize and eliminate tumor cells.
